Telehealth on the rise, page-264

So we have a remote diagnostic tool for respiratory disease. Unfortunately it can't provide remote treatment, and the vast majority of patients would either already be known or still require to actually see a physician for definitive diagnosis and to receive treatment.

So its not clear to me just how valuable this tool really is or how much revenue it would be really likely to generate. I have to say, at a market cap of over $200m, it seems likely to be pretty fully priced for the benefit it could possibly to bring to patients. Is there something I have missed in the presentation?